BAFNA PHARMACEUTICALS LTD.

Bafna Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. This measure is intended to prevent potential insider trading activities during the period leading up to and immediately following the financial results announcement.

Bafna Pharmaceuticals Ltd announced the retirement of Mr. Navin Kumar as an Independent Director, effective June 22, 2026, upon completion of his first term. Consequently, he will also step down as Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has reconstituted these committees effective June 23, 2026, with new chairpersons and members appointed. Bafna Pharmaceuticals confirmed that the board and committee compositions remain compliant with applicable regulations.

Bafna Pharmaceuticals Ltd announced the retirement of Mr. Navin Kumar as an Independent Director, effective June 22, 2026, upon completion of his first term. Consequently, he will also step down as Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has reconstituted these committees effective June 23, 2026, with new chairpersons and members appointed. Bafna Pharmaceuticals confirmed that the board and committee compositions remain compliant with applicable laws post-retirement.

Bafna Pharmaceuticals Ltd announced its audited financial results for the quarter and year ended March 31, 2026. Key highlights include revenue from operations of ₹8,213.83 lakhs and the Board's approval of these results on May 29, 2026. The company is contesting GST demands and recovery of GST refunds, but anticipates no adverse financial outcome. The auditor's report has an unmodified opinion.

Bafna Pharmaceuticals Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The company reported revenue from operations of ₹15,061.74 lakhs for the year ended March 31, 2026, as compared to ₹14,559.92 lakhs in the previous year. The Board meeting commenced at 02:00 P.M and concluded at 04:00 P.M.

Bafna Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026. The trading window for designated persons remains closed from April 1, 2026, to May 31, 2026.

Bafna Pharmaceuticals Ltd responded to queries from the stock exchanges (NSE and BSE) regarding significant movement in its share price. The company stated that it is neither aware of nor has it withheld any information or event that could have a bearing on the share price movement. Bafna Pharmaceuticals attributed the fluctuations to market-driven factors, general market conditions, and investor sentiments, asserting that its management has no control over such movements. The company also confirmed its ongoing compliance with all applicable disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bafna Pharmaceuticals Ltd announced the appointment of M/s. K. S. Rao & Co., Chartered Accountants, Chennai as the Internal Auditor and M/s. N. Sivashankaran & Co., Cost Accountants, Chennai as the Cost Auditor for the financial year 2026-2027. The appointments were approved in a Board Meeting held on March 27, 2026. M/s. K. S. Rao & Co. is a reputed audit firm with over 4 decades of experience, while M/s. N. Sivashankaran & Co. is a well-established firm with extensive experience in cost and management accounting, cost audit, and financial consultancy.

Bafna Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives, in accordance with SEBI regulations and the company's Code of Conduct for Prevention of Insider Trading. The trading window will remain closed from April 01, 2026 till 48 hours after the declaration of Audited Financial Results for the Quarter and Financial Year ending March 31, 2026. This move is aimed at preventing insider trading during the sensitive period surrounding the release of financial results.

Bafna Pharmaceuticals Ltd has responded to the Stock Exchange's query regarding the movement in its share price. The company is not aware of any information or event that may have influenced this movement, attributing it to general market conditions and investor sentiments. The company and its management have no control over the share price movement and assure compliance with all applicable disclosure requirements.